The safety profile of imatinib in CML and GIST: long-term considerations (Q37895973)

25 August 2017

1 reference

title

The safety profile of imatinib in CML and GIST: long-term considerations (English)

1 reference

25 August 2017

1 reference

Eirini Thanopoulou

1

1 reference

PubMed ID

21717109

25 August 2017

Ian Judson

series ordinal

2

1 reference

25 August 2017

30 June 2011

1 reference

25 August 2017

Archives of Toxicology

1 reference

25 August 2017

86

1 reference

25 August 2017

1

1 reference

25 August 2017

1-12

1 reference

https://scigraph.springernature.com/pub.10.1007/s00204-011-0729-7

25 August 2017

0 references

cites work

Congestive heart failure is a rare event in patients receiving imatinib therapy

1 reference

https://api.crossref.org/works/10.1007%2FS00204-011-0729-7

Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-011-0729-7

Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-011-0729-7

Imatinib mesylate may improve fasting blood glucose in diabetic Ph+ chronic myelogenous leukemia patients responsive to treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-011-0729-7

Impact of interactions of cellular components of the bone marrow microenvironment on hematopoietic stem and progenitor cell function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-011-0729-7

Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimizati

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-011-0729-7

Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-011-0729-7

KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-011-0729-7

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-011-0729-7

Imatinib as a potential antiresorptive therapy for bone disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-011-0729-7

Severe periorbital edema secondary to STI571 (Gleevec).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-011-0729-7

An anticancer C-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxic

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-011-0729-7

Long-term imatinib therapy promotes bone formation in CML patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-011-0729-7

Imatinib (STI571)-mediated changes in glucose metabolism in human leukemia BCR-ABL-positive cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-011-0729-7

Quantification of the anticancer agent STI-571 in erythrocytes and plasma by measurement of sediment technology and liquid chromatography-tandem mass spectrometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-011-0729-7

Amelioration of diabetes by imatinib mesylate (Gleevec): role of beta-cell NF-kappaB activation and anti-apoptotic preconditioning

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-011-0729-7

Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-011-0729-7

Molecular correlates of imatinib resistance in gastrointestinal stromal tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-011-0729-7

Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-011-0729-7

Increased cortical bone mineralization in imatinib treated patients with chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-011-0729-7

Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-011-0729-7

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-011-0729-7

Prognostic factors influencing surgical management and outcome of gastrointestinal stromal tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-011-0729-7

Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-011-0729-7

Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-011-0729-7

Gastrointestinal stromal tumors: recent advances in understanding of their biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-011-0729-7

Efficacy and safety profile of imatinib mesylate (ST1571) in Japanese patients with advanced gastrointestinal stromal tumors: a phase II study (STI571B1202).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-011-0729-7

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-011-0729-7

Decreased bone turnover despite persistent secondary hyperparathyroidism during prolonged treatment with imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-011-0729-7

Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-011-0729-7

Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of liver dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-011-0729-7

Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-011-0729-7

Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-011-0729-7

Imatinib attenuates end-organ damage in hypertensive homozygous TGR(mRen2)27 rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-011-0729-7

Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-011-0729-7

Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-011-0729-7

Dysregulation of bone remodeling by imatinib mesylate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-011-0729-7

Imatinib and regression of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-011-0729-7

Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-011-0729-7

Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein, adiponectin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-011-0729-7

A long-term follow-up of the imatinib mesylate treatment for the patients with recurrent gastrointestinal stromal tumor (GIST): the liver metastasis and the outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-011-0729-7

Imatinib does not induce cardiac left ventricular failure in gastrointestinal stromal tumours patients: Analyis of EORTC-ISG-AGITG study 62005

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-011-0729-7

Mice deficient in Abl are osteoporotic and have defects in osteoblast maturation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00204-011-0729-7

10.1007/S00204-011-0729-7

21 January 2018

Identifiers

DOI

1 reference

25 August 2017

1 reference

PubMed ID

21717109